Journal article

Chemoimmunotherapy May Overcome the Adverse Prognostic Significance of 11q Deletion in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Apostolia-Maria Tsimberidou, Constantine Tam, Lynne V Abruzzo, Susan O'Brien, William G Wierda, Susan Lerner, Hagop M Kantarjian, Michael J Keating

CANCER | WILEY | Published : 2009

Abstract

BACKGROUND: An 11q22 deletion is considered an independent factor predicting poor survival in chronic lymphocytic leukemia (CLL). METHODS: We searched the electronic CLL database for consecutive patients who presented to the M. D. Anderson Cancer Center Department of Leukemia from October 2003 to April 2007 with untreated CLL and who had an 11q22 deletion, detected by fluorescence in situ hybridization (FISH) analysis of bone marrow samples. FISH analysis was performed using the following probes: trisomy 12 (12p11.1-q11), TP53 (17p13.1), ATM (11q22.3), LAMP1 (13q34), and D13S319 loci (13q14.3). RESULTS: Sixty-nine patients with untreated CLL with an 11q22 deletion were identified. The median..

View full abstract

Grants

Awarded by NATIONAL CANCER INSTITUTE


Funding Acknowledgements

This work is supported in part by a career development award from the American Society of Clinical Oncology to Apostolia-Maria Tsimberidou. Michael J. Kcating receives both honoraria and research support from Bayer Oncology and Genentech. Susan O'Brien receives research support from Genentech, Berlex, Bingen idec, Eli Lily, Novartis, Bristol-Myers-Squlibb, Gerninx, and Gentra; she is a consultant to Genta, Sanofi-Aventis, and Celgene and is on the scientific advisory boards of Geminx, Biogen Idec, and Fli Lily,